ArticleInorganic chemistry2026
Fluorescent NHC Gold(I) Complexes as Tools for Target Identification and Metallomic Studies in Cancer Cells.
Article in Inorganic chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
In recent years, gold(I) complexes have attracted increasing interest as an alternative to conventional metallo-chemotherapeutic agents. Their mode of action differs significantly from that of traditional platinum-based drugs. However, the identification of their intracellular targets and the elucidation of their mechanisms of action remain major challenges, largely due to the lack of suitable molecular tools for tracking these compounds in biological systems. To address these issues, three novel gold(I) complexes bearing two different fluorescent labels were synthesized and characterized. These complexes include an N-heterocyclic monocarbene gold(I) complex 3 and the corresponding biscarbene 4, both of which are functionalized with an anthracenyl moiety, as well as an NHC gold(I) monocarbene complex bearing a BODIPY label 5. The specific aim of this study was to generate trackable metallodrug models for mechanistic and metallomics-oriented research. These compounds were characterized using 1H and 13C NMR spectroscopy and elemental analysis. The crystallographic structure of the anthracenyl gold monocarbene was also determined. Interaction studies with human serum albumin (HSA) using UV-vis absorption spectroscopy and ESI-MS provided clear evidence of metallodrug-protein interactions. The uptake of the complexes in A2780 ovarian cancer cells was measured using fluorescence-activated cell sorting (FACS) cytofluorimetry, which indicated strong cellular uptake for the anthracenyl-labeled compounds 3 and 4. A cell fractionation approach was used for the quantitative analysis of subcellular drug disposition. These approaches collectively enabled a direct visualization of the intracellular fate of the gold complexes, providing a framework for correlating cellular distribution with biological activity. Finally, the gold complexes bearing the anthracenyl probe were evaluated for their cytotoxic activity in cisplatin-sensitive and -resistant A2780 cancer cells; the BODIPY complex could not be evaluated due to its insolubility. Overall, this study provides solid evidence that gold complexes bearing the anthracenyl probe retain significant cytotoxic properties and enable monitoring the uptake and fate of these gold species inside cancer cells, thus providing a proof-of-concept that fluorescently labeled gold complexes can serve as powerful tools for mechanistic investigations, including metallomics and proteomics-oriented studies aimed at identifying molecular targets and affected pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.